3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Neoplasms
41
Breast Neoplasms
40
Lung Neoplasms
25
Carcinoma, Non-Small-Cell Lung
20
Colorectal Neoplasms
19
Uterine Cervical Neoplasms
13
Prostatic Neoplasms
13
Head and Neck Neoplasms
11
Carcinoma, Hepatocellular
11
Pancreatic Neoplasms
10
Melanoma
10
Ovarian Neoplasms
9
Neoplastic Cells, Circulating
7
Myelodysplastic Syndromes
7
Glioma
7
Esophageal Neoplasms
7
Endometrial Neoplasms
7
Brain Neoplasms
7
Sarcoma
6
Multiple Myeloma
6
Gastrointestinal Neoplasms
6
Carcinoma, Renal Cell
6
Triple Negative Breast Neoplasms
5
Neoplasm Metastasis
5
Leukemia, Myeloid, Acute
5
Disease
5
Colonic Neoplasms
5
Uveal Melanoma
4
Skin Neoplasms
4
Neoplasm, Residual
4
Interventions
rozanolixizumab
8
zilucoplan
7
ravulizumab
6
fludarabine
5
efgartigimod alfa
5
Cyclophosphamide
5
telitacicept
3
Prednisone
3
inebilizumab
2
Rituximab
2
Pyridostigmine Bromide
2
tofacitinib
1
thymoglobulin
1
talquetamab
1
remibrutinib
1
prednylidene
1
iptacopan
1
eculizumab
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
Walk Test
1
Therapeutics
1
Tacrolimus
1
Steroids
1
Robotic Surgical Procedures
1
Psychodrama
1
Prednisolone
1
Plasma Exchange
1
Peripheral Blood Stem Cell Transplantation
1
Oxaloacetic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myasthenia Gravis
×
Blood Specimen Collection
×
1 year
×
Clear all
NCT00704626
2026-05-18
SAA
University of California, Davis
Enrolling by invitation
120 enrolled